NRXP Clinical trials

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

Published August 27, 2025 at 12:03 PM

WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced its expanded access policy for NRX-100 (preservative-free ketamine) based on grant of Fast Track designation for NRX-100 in the treatment of suicidal ideation in patients with depression, including bipolar depression.

Related Questions

How will the expanded access policy and Fast Track designation for NRX-100 affect NRXP's short‑term stock volatility and price target? What is the expected timeline for NRX-100 to progress from expanded access to pivotal Phase III trials and potential FDA approval, and how does that compare to competitors' ketamine or rapid‑acting antidepressant programs? What is the estimated market opportunity and pricing power for a preservative‑free ketamine formulation targeting suicidal ideation in major depressive and bipolar depression patients, and how might this influence NRXP's long‑term revenue outlook?